KR20240019157A - 세로토닌 수용체의 디메톡시페닐알킬아민 활성화제 - Google Patents

세로토닌 수용체의 디메톡시페닐알킬아민 활성화제 Download PDF

Info

Publication number
KR20240019157A
KR20240019157A KR1020237044143A KR20237044143A KR20240019157A KR 20240019157 A KR20240019157 A KR 20240019157A KR 1020237044143 A KR1020237044143 A KR 1020237044143A KR 20237044143 A KR20237044143 A KR 20237044143A KR 20240019157 A KR20240019157 A KR 20240019157A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
hydrogen
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044143A
Other languages
English (en)
Korean (ko)
Inventor
로버트 비. 페르니
글렌 쇼트
벤자민 로버트 디프란체스코
탄위르 칸
Original Assignee
엔테오제닉스 바이오사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔테오제닉스 바이오사이언스, 인크. filed Critical 엔테오제닉스 바이오사이언스, 인크.
Publication of KR20240019157A publication Critical patent/KR20240019157A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237044143A 2021-06-08 2022-06-08 세로토닌 수용체의 디메톡시페닐알킬아민 활성화제 Pending KR20240019157A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163208391P 2021-06-08 2021-06-08
US63/208,391 2021-06-08
US202163241662P 2021-09-08 2021-09-08
US63/241,662 2021-09-08
PCT/US2022/032715 WO2022261240A2 (en) 2021-06-08 2022-06-08 Dimethoxyphenylalkylamine activators of serotonin receptors

Publications (1)

Publication Number Publication Date
KR20240019157A true KR20240019157A (ko) 2024-02-14

Family

ID=84426423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044143A Pending KR20240019157A (ko) 2021-06-08 2022-06-08 세로토닌 수용체의 디메톡시페닐알킬아민 활성화제

Country Status (11)

Country Link
US (3) US11926574B2 (https=)
EP (1) EP4351548A4 (https=)
JP (1) JP2024520832A (https=)
KR (1) KR20240019157A (https=)
AU (1) AU2022288926A1 (https=)
BR (1) BR112023025599A2 (https=)
CA (1) CA3216096A1 (https=)
CL (1) CL2023003662A1 (https=)
IL (1) IL309074A (https=)
MX (1) MX2023014630A (https=)
WO (1) WO2022261240A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
EP4608806A1 (en) * 2022-10-28 2025-09-03 Cybin IRL Limited Phenethylamine compounds, compositions, and methods of use
WO2024124056A1 (en) * 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637735A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4637736A1 (en) * 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045180B2 (ja) 1977-05-17 1985-10-08 第一製薬株式会社 2−アミノテトラリン誘導体
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5807897A (en) 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
DK1859798T3 (en) * 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
BRPI0713736A2 (pt) 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US20080318957A1 (en) 2007-05-11 2008-12-25 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2011047165A1 (en) 2009-10-16 2011-04-21 Southern Illinois University Edwardsville Methods for treating memory impairment
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
GB201409516D0 (en) * 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US10454900B2 (en) 2015-09-25 2019-10-22 Mcafee, Llc Remote authentication and passwordless password reset
CN110177581B (zh) 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
WO2019084338A1 (en) 2017-10-25 2019-05-02 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
EP4417596B1 (en) 2017-11-06 2026-04-29 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a-beta-42 oligomer formation
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
AU2019324952B2 (en) * 2018-08-22 2024-10-24 University Of Technology Sydney NBOMe test
JP7731868B2 (ja) 2019-08-02 2025-09-01 エースロット,インコーポレイテッド TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US12534425B2 (en) 2020-06-29 2026-01-27 Gilgamesh Pharmaceuticals, Inc. Phenalkylamines and methods of treating mood disorders
CN119285527A (zh) 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
JP2024512796A (ja) 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク. サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
EP4337220A4 (en) 2021-05-11 2025-07-02 Saint Josephs Univ SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
CA3239571A1 (en) 2021-12-15 2023-06-22 Noel Aaron Powell Fused pyrrolidine psychoplastogens and uses thereof
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
WO2024124056A1 (en) 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637736A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
EP4637735A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4680236A2 (en) 2023-03-16 2026-01-21 ATAI Therapeutics, Inc. 3-alkylamine indole activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Also Published As

Publication number Publication date
WO2022261240A3 (en) 2023-01-05
WO2022261240A2 (en) 2022-12-15
CL2023003662A1 (es) 2024-05-03
US20240294461A1 (en) 2024-09-05
IL309074A (en) 2024-02-01
BR112023025599A2 (pt) 2024-02-20
US20250282712A1 (en) 2025-09-11
MX2023014630A (es) 2024-01-30
US12351537B2 (en) 2025-07-08
CA3216096A1 (en) 2022-12-15
EP4351548A2 (en) 2024-04-17
US20230138118A1 (en) 2023-05-04
EP4351548A4 (en) 2025-04-30
AU2022288926A1 (en) 2023-10-19
US11926574B2 (en) 2024-03-12
JP2024520832A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
KR20240019157A (ko) 세로토닌 수용체의 디메톡시페닐알킬아민 활성화제
US12344570B2 (en) Aminotetraline activators of serotonin receptors
JP7564942B2 (ja) Retキナーゼ阻害剤としてのヘテロ芳香族環化合物及びその製造と使用
CN109641887B (zh) 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物
CA3102848A1 (en) Novel salts and crystals
Mashayekhi et al. Synthesis, antimycobacterial and anticancer activity of novel indole-based thiosemicarbazones
HU214870B (hu) N-(3-Amino-propil)-N-fenil-5,6,7,8-tetrahidronaftalin-2-karboxamid-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
WO2024192150A2 (en) 3-alkylamine indole activators of serotonin receptors
EP4637735A1 (en) Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
JP2013514327A (ja) mGluR5受容体のアロステリック調節因子としての二環式チアゾール
EP4201924B1 (en) Ire1 small molecule inhibitors
US20030216379A1 (en) Substituted fused pyrazolecarboxylic acid arylamides and related compounds
JP2022537330A (ja) インダゾール誘導体、その製造方法及び医薬上のその使用
WO2020052349A1 (zh) Fgfr抑制剂、其制备方法和应用
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
CN107501270B (zh) 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用
CN117500487A (zh) 血清素受体的二甲氧基苯基烷基胺激活剂
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
KR20210081369A (ko) 1,2,3,4-테트라히드로퀴녹살린 유도체, 이의 제조 방법 및 응용
CN111187257B (zh) Ret受体酪氨酸激酶抑制剂
Herold et al. Novel 4-aryl-pyrido [1, 2-c] pyrimidines with dual SSRI and 5-HT1A activity, Part 1
JP7254075B2 (ja) キサンチン誘導体及びbetタンパク質のブロモドメインの阻害剤としてのその使用
WO2019015689A1 (zh) 手性3-奎宁环酮类化合物、制备方法及用途
CN117285455A (zh) 2-苯甲酰基吲哚类化合物及其应用
EA040009B1 (ru) Гетероарилзамещенные пирроло[2,3-d]пиримидины в качестве ингибиторов янус-киназы

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20240723

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250424

Comment text: Request for Examination of Application